ReviewCurrent atherosclerosis reports2026
Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewTo evaluate the evidence supporting combined sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes, focusing on cardiometabolic outcomes and practical treatment approaches. RECENT
findingsCardiovascular outcomes trials and real-world studies indicate that SGLT2is and GLP-1RAs confer complementary, non-redundant cardiovascular, kidney, and metabolic benefits. SGLT2is primarily reduce hospitalization for heart failure and slow kidney disease progression, while GLP-1RAs more effectively reduce atherosclerotic events, particularly stroke; dedicated kidney-outcome and heart-failure trials of GLP-1RAs in chronic kidney disease and obesity-related heart failure with preserved ejection fraction have further broadened their role. Randomized data show that each class retains its benefit irrespective of background use of the other, supporting independent mechanisms; whether this translates into reductions in hard outcomes is being tested prospectively. Emerging evidence supports a phenotype-guided approach that aligns therapy with dominant comorbidities such as atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and obesity. Despite advances in pharmacotherapy, substantial cardiometabolic risk remains in type 2 diabetes. Combined SGLT2i and GLP-1RA therapy addresses multiple risk domains through complementary mechanisms and may be most effective within a phenotype-guided framework. This framework prioritizes therapy according to predominant comorbidity and reserves combination treatment for individuals with overlapping high-risk phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.